FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine. Disclosed is a method of activating the nuclear factor of the short-chain Kappa activated cell enhancer B (NF-κB) in the digestive tract of an organism in need thereof. Method involves administering to an organism of an effective amount of a composition consisting of eggshell membranes of natural origin.
EFFECT: invention provides effective treatment of conditions associated with NF-κB.
14 cl, 5 dwg, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR EVALUATING MEDICINES FOR ARTICULAR CARTILAGE | 2016 |
|
RU2714312C1 |
| EMPLOYMENT OF (R)-ARYLPROPIONIC ACIDS TO PREPARE DRUGS FOR TREATMENT OF HUMANS AND ANIMALS LIABLE TO BE THERAPEUTICALLY AFFECTED VIA NF-κB ACTIVATION INHIBITION | 2000 |
|
RU2250103C2 |
| APPLICATION OF COMPOSITION CONTAINING ENISAMIUM IODIDE AS ACTIVE INGREDIENT | 2022 |
|
RU2815779C1 |
| METHOD OF INHIBITING KAPPA NUCLEAR FACTOR WITH THE USE OF POTASSIUM 5-HYDROXYNICOTINATE IN A CELL CULTURE | 2017 |
|
RU2675693C1 |
| 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE-METHYL, POLYMORPHOUS FORMS AND METHODS FOR USE THEREOF | 2014 |
|
RU2693833C2 |
| METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | 2013 |
|
RU2667960C2 |
| USE OF ARSENIC COMPOUNDS TO TREAT TISSUE OR ORGAN REJECTION | 2013 |
|
RU2665362C2 |
| METHOD FOR INHIBITING NUCLEAR FACTOR KAPPA B WITH USE OF 5-HYDROXYNICOTINATE 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE IN CELL CULTURE | 2017 |
|
RU2674443C1 |
| MEDICINAL EXTRACTS OF AMBROSIA PLANTS | 2016 |
|
RU2763021C2 |
| AGONISTS OF NEUROTROPHIN RECEPTORS AND THEIR USE AS MEDICAMENTS | 2011 |
|
RU2606622C2 |
